123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.
Identifieur interne : 002859 ( Ncbi/Checkpoint ); précédent : 002858; suivant : 002860123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.
Auteurs : Olivier Rascol [France] ; Ludwig ScheloskySource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- 3-Iodobenzylguanidine (diagnostic use), Autonomic Nervous System Diseases (etiology), Autonomic Nervous System Diseases (radionuclide imaging), Heart (physiopathology), Heart (radionuclide imaging), Humans, Lewy Body Disease (complications), Lewy Body Disease (radionuclide imaging), Parkinson Disease (radionuclide imaging), Parkinsonian Disorders (radionuclide imaging), Radiopharmaceuticals (diagnostic use).
- MESH :
- chemical , diagnostic use : 3-Iodobenzylguanidine, Radiopharmaceuticals.
- complications : Lewy Body Disease.
- etiology : Autonomic Nervous System Diseases.
- physiopathology : Heart.
- radionuclide imaging : Autonomic Nervous System Diseases, Heart, Lewy Body Disease, Parkinson Disease, Parkinsonian Disorders.
- Humans.
Abstract
Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post-ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. (123)I-metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. "Atypical" parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy.
DOI: 10.1002/mds.22499
PubMed: 19877202
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001B24
- to stream PubMed, to step Curation: 001B24
- to stream PubMed, to step Checkpoint: 001F89
- to stream Ncbi, to step Merge: 002859
- to stream Ncbi, to step Curation: 002859
Links to Exploration step
pubmed:19877202Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><nlm:affiliation>INSERM CIC-P302 and UMR-825, Department of Clinical Pharmacology, Faculté de Médecine, CHU and University UPS of Toulouse, Toulouse, France. rascol@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM CIC-P302 and UMR-825, Department of Clinical Pharmacology, Faculté de Médecine, CHU and University UPS of Toulouse, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22499</idno><idno type="RBID">pubmed:19877202</idno><idno type="pmid">19877202</idno><idno type="wicri:Area/PubMed/Corpus">001B24</idno><idno type="wicri:Area/PubMed/Curation">001B24</idno><idno type="wicri:Area/PubMed/Checkpoint">001F89</idno><idno type="wicri:Area/Ncbi/Merge">002859</idno><idno type="wicri:Area/Ncbi/Curation">002859</idno><idno type="wicri:Area/Ncbi/Checkpoint">002859</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><nlm:affiliation>INSERM CIC-P302 and UMR-825, Department of Clinical Pharmacology, Faculté de Médecine, CHU and University UPS of Toulouse, Toulouse, France. rascol@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM CIC-P302 and UMR-825, Department of Clinical Pharmacology, Faculté de Médecine, CHU and University UPS of Toulouse, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Iodobenzylguanidine (diagnostic use)</term><term>Autonomic Nervous System Diseases (etiology)</term><term>Autonomic Nervous System Diseases (radionuclide imaging)</term><term>Heart (physiopathology)</term><term>Heart (radionuclide imaging)</term><term>Humans</term><term>Lewy Body Disease (complications)</term><term>Lewy Body Disease (radionuclide imaging)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Parkinsonian Disorders (radionuclide imaging)</term><term>Radiopharmaceuticals (diagnostic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lewy Body Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Autonomic Nervous System Diseases</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Heart</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Heart</term><term>Lewy Body Disease</term><term>Parkinson Disease</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post-ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. (123)I-metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. "Atypical" parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy.</div></front></TEI><affiliations><list><country><li>France</li></country><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name></noCountry><country name="France"><noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002859 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 002859 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:19877202
|texte= 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:19877202" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |